Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01207414 · ClinicalTrials.gov registry record · Phase 4
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A Phase 4 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 4
- Development phase
- 501
- Enrollment target
NCT01207414 is a Phase 4 study that has completed, run by Novartis. The registered enrollment target is 501 participants.
The verdict
NCT01207414, a Phase 4 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 501 participants
- Enrollment target
Study Summary
Evaluate the clinical outcome of two switching strategies to iloperidone treatment in adult subjects with schizophrenia who require a change in their current antipsychotic treatment of risperidone, olanzapine, or aripiprazole due to suboptimal efficacy and/or safety/tolerability reasons.
Interventions
- DRUG iloperidone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 501 participants |
| Start Date | 2010-08 |
| Est. Completion | 2012-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01207414
The ClinicalTrials.gov registry entry for NCT01207414 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 501 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which iloperidone is the first listed.
NCT01207414 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01207414 about?
NCT01207414 is a clinical study titled "Switching to Iloperidone From Other Antipsychotics in Schizophrenia". Evaluate the clinical outcome of two switching strategies to iloperidone treatment in adult subjects with schizophrenia who require a change in their current antipsychotic treatment of risperidone, olanzapine, or aripiprazole due to suboptimal efficacy and/or safety/tolerability reasons.
What is the current status of trial NCT01207414?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 501 participants. The study started on 2010-08. Estimated completion is 2012-01.
What interventions are being tested in trial NCT01207414?
The interventions under investigation include: iloperidone (DRUG).
Who is sponsoring clinical trial NCT01207414?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.